STILNOX (zolpidem) – Measures taken to further mitigate the risk of dependence and abuse

Sanofi-aventis would like to inform healthcare professionals about measures taken to further mitigate the risk of dependence and abuse with zolpidem. These measures will be implemented via restriction of indication and strengthening of safety information in the local package inserts (PI) for STILNOX (both immediate-release and extended-release formulations). Healthcare professionals are reminded of the information that is present or will be updated in the STILNOX PI, including restriction of indication to short-term treatment of insomnia, recommendations on treatment duration and warnings on risk of dependence and abuse. Please refer to the letter for details.

 
 
Healthcare professional, Therapeutic Products
Published:

Dear Healthcare Professional Letters

12 Dec 2019

Only abstracts of the Dear Healthcare Professional Letters (DHCPL) are provided on this website. Details of the letters can be found on the MOH Alert System, which is accessible via the Health Professionals Portal (HPP). HPP is a one-stop portal for all healthcare professionals in Singapore. Dentists, medical doctors and pharmacists may access HPP at https://www.hpp.moh.gov.sg/, and follow the procedures below to access the MOH Alert system.

Step 1: Scroll down to the bottom navigation panel of the HPP web page. Under the Healthcare Professionals section, expand the dropdown option for ‘Healthcare Professional Portal’ and select your profession. You will be redirected to the specific HPP web page to log in.

Step 2: Click on the Restricted Content icon on the left panel of the web page and log in via SingPass.

Step 3: Click on the MOH Alert icon under the ‘Applications’ section.

Step 4: Click on the Drug Alert tab to view the DHCPLs.